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vaginal mucosa the D0.1cc was considered. Statistical 
significance of the results was proven by a Wilcoxon test for 
paired samples (significant p-value <0.05) 
 
Results: 
 
 
Table 1 shows the obtained values for D90, V90, COIN, DHI 
and %CC for the investigated OM. No significant differences 
resulted among the OM in terms of target coverage (D90 and 
V90) and bladder and rectum sparing (D2cc).  
 
The figure shows average DVHs of the PTV over all 12 cases. 
DVHs obtained with homogIPSA and HIPO show a steeper 
gradient, resulting in smaller volumes exposed to high doses. 
homogIPSA and HIPO result in significantly better values of 
COIN, DHI e %CC values. Furthermore, homogIPSA shows the 
lowest value for the D0.1cc to the mucosa. No differences 
were evidenced between the use of MVC applicators with 
diameters of 25mm and 30mm. 
 
Conclusion: HIPO and homogIPSA should be preferred due to 
their ability to get improved dose homogeneity to the target 
and reduced hot spots to the vaginal mucosa. This is achieved 
by a more effective distribution of source dwelling times 
between central and peripheral catheters. It has to be noted 
that all investigated OM require experience of the planner 
and are not completely user independent. 
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Purpose or Objective: To investigate the dosimetric 
characteristics of GMS BT-125-1 I-125 radioactive seed, 
including dose rate constant, radial dose functions and 
anisotropy functions. 
 
Material and Methods: Dosimetric parameters of GMS BT-
125-1 I-125 seed, including dose rate constant, radial dose 
functions and anisotropy functions were calculated using the 
Monte Carlo code of MCNP5, and measured using 
thermoluminescent dosimeters (TLDs). Monte Carlo 
calculations were also performed for the PharmaSeed BT-125-
1 I-125 seed, PharmaSeed BT-125-2 I-125 seed and model 
6711 I-125 seed. The dosimetric parameters of GMS BT-125-1 
I-125 seed were compared with those of PharmaSeed BT-125-
1 I-125 seed, PharmaSeed BT-125-2 I-125 seed and model 
6711 I-125 seed. The measured results were compared with 
those of Monte Carlo simulation for GMS BT-125-1 I-125 seed. 
 
Results: The MCNP5 calculated dose rate constant of GMS BT-
125-1 I-125 seed was 1.011 . The experimental measured 
dose rate constant of GMS BT-125-1 I-125 seed was 0.967 . 
For radial dose function, the difference between GMS BT-
125-1 I-125 seed and PharmaSeed BT-125-2 I-125 seed were 
typically less than 2.0% with a maximum of 3.3 %. The largest 
differences were 8.1% and 6.2% compared with PharmaSeed 
BT-125-1 and model 6711 I-125 seed, respectively. For 
anisotropy functions, the difference between GMS BT-125-1 I-
125 seed and PharmaSeed BT-125-2 I-125 seed was typically 
<10% with a maximum of about 9.6% when the polar angle 
was larger than 10 degree, and 22.9% when the polar angle 
was smaller than 10 degree. Compared with Monte Carlo 
simulation, the largest differences of radial dose functions 
and anisotropy functions were 14.5% and 29.1%, respectively.  
 
Conclusion: The measured dose rate constant, radial dose 
functions and anisotropy functions for GMS BT-125-1 I-125 
seed showed good agreement with Monte Carlo calculated 
values. The dosimetric parameters of GMS BT-125-1 I-125 
seed are similar to those of PharmaSeed BT-125-2 I-125 seed.  
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Purpose or Objective: The aim of this study was: (i) to 
design a new high-dose-rate (HDR) brachytherapy applicator 
for treating surface lesions larger than 3 cm in diameter and 
up to 5 cm size, using the microSelectron-HDR afterloader 
(Elekta Brachytherapy); (ii) to calculate by means of the 
Monte Carlo (MC) method the dose distribution around the 
new applicator when it is placed over a water phantom; and 
(iii) to validate experimentally the water dose distributions. 
 
Material and Methods: The new applicator is made of 
tungsten, and consists on a set of interchangeable collimators 
without flattening filter. It makes use of three catheters to 
allocate the source at prefixed dwell positions and times to 
produce a homogeneous dose distribution at 3 mm depth in 
the water phantom. The Penelope2008 MC code was used to 
optimize dwell positions and dwell times. Next, the dose 
distribution in a water phantom and leakage dose distribution 
were calculated. Finally, MC data were validated 
experimentally by measuring: dose distributions with 
radiochromic EBT3 films (ISP) for an 192Ir mHDR-v2 source; 
percentage depth-dose (PDD) curve with the parallel-plate 
ionization chamber Advanced Markus (PTW); and absolute 
dose rate with EBT3 films and the PinPoint T31016 (PTW) 
ionization chamber. 
 
Results: PDD and off-axis profiles were obtained normalized 
at a depth of 3 mm along the central applicator axis in a 
cylindrical water phantom. These data can be used for 
treatment planning. Leakage was also scored. The dose 
distributions, PDD, and absolute dose rate calculated agree 
within experimental uncertainties with the doses measured. 
 
Conclusion: The new applicator and the dosimetric data 
provided here will be a valuable tool in clinical practice, 
making treatment of large skin lesions simpler, faster, safer, 
and with minimized dose to surrounding healthy tissues when 
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compared to electron therapy or brachytherapy with moulds 
and flaps. 
 
EP-1993  
Dose evaluation at organs at risk in vaginal cuff 
brachytherapy 
J. Wiercińska
1Oncology Center Bydgoszcz, Medical Physics Department, 
Bydgoszcz, Poland 
1,2, R. Kabacińska1, J. Terlikiewicz2,3, A. 
Lebioda2,3, A. Wronczewska3, R. Makarewicz2,3 
2Collegium Medicum- Nicolaus Copernicus University- Toruń, 
Department of Oncology and Brachytherapy, Bydgoszcz, 
Poland 
3Oncology Center Bydgoszcz, Brachytherapy Department, 
Bydgoszcz, Poland 
 
Purpose or Objective: Vaginal cuff brachytherapy with the 
dose prescribed at 0.5 cm depth from the applicator surface 
has been the standard treatment for gynaecological cancer 
patient after histerectomy for years. The implementation of 
computed tomography based (CT-based) plans caused 
changes in the standard approach in our hospital. We 
narrowed the planning target volume (PTV) in order to meet 
our in-house constraints requirement for organs at risk (OARs) 
in some cases. The aim of the study was to analyze doses at 
OARs in real adjusted image-based plans and in standard 0.5 
cm normalized plans. 
 
Material and Methods: Treatment plans of recent, 
consecutive 70 patients treated with high dose rate vaginal 
cuff CT-based brachytherapy were analyzed retrospectively. 
Dose normalization points and optimization methods were 
adjusted whenever standard approach wasn't suitable to 
meet all dose constraints for OARs (adjusted plan - AP). The 
second, standard treatment plan (SP) was created for every 
AP. APs were divided into three groups based on overdosage 
at definite OAR: Bladder Group (B group), Rectum Group (R 
group) and Bladder & Rectum Group (B&R group). Comparison 
of doses at the most exposed 0.1cc (D0.1cc) and 2cc (D2cc) 
of bladder and rectum between AP and SP was made in all 
three groups. 
 
Results: Vaginal cylinders of 10 to 35 mm radius were used. 
For 54% of all 70 cases the standard approach wasn't deemed 
suitable, and the treatment plan was adjusted (SP- 32 cases, 
AP-38 cases). 53% of the APs were assigned to the R group, 
21% to the B group and 26% to the B&R group. Mean values of 
rectum doses in R Group were 96.6% and 112.0% for RD0.1cc 
and 74.4% and 83.6% for RD2cc for AP and SP respectively. 
Mean values of bladder doses in B Group were 97.2% and 
108.0% for BD0.1cc and 79.3% and 86.9% for BD2cc for AP and 
SP respectively. In B&R Group mean values of RD0.1cc were 
93.1% and 108.9% and mean values of RD2cc were 71.8% and 
81.1% for AP and SP respectively, mean values of BD0.1cc 
were 94.4% and 105.9% and mean values of BD2cc were 77.5% 
and 84.4% for AP and SP respectively. The doses are 
presented as a percentage of prescribed dose. Dose 
differences between both plans in all three groups were 
statistically significant. 
 
Conclusion: Standard approach with dose points at 0.5 cm 
from the applicator surface is not suitable for all patients and 
can increase the risk of bladder or rectum complications. CT-
based plan allowing dose evaluation at OARs should be 
practiced on a daily basis. 
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Purpose or Objective: Brachytherapy has recently advanced 
towards personalized planning dosimetry with the 
commercial availability of image-based treatment planning 
systems for Ir-192. This marks an improvement over TG-43 
based planning dosimetry that relies on source specific data 
pre-calculated in a standard sized geometry of homogeneous 
water, hence disregarding patient-specific radiation scatter 
conditions and the radiological differences of tissue or 
applicator materials from water. The aim of this work is to 
perform a comparative study of the effect of these factors in 
Co-60 and Ir-192 HDR brachytherapy. 
 
Material and Methods: Ten clinical cases were studied for 
each of three disease cites considered (gynaecological, 
esophagus and breast). Two treatment plans were prepared 
for each case using the TG-43 option of a commercially 
available system (SagiPlan) with an Ir-192 (Ir2.A85-2) and a 
Co-60 (Co0.A86) HDR source. The plans were exported in 
dicom RT format. Corresponding personalized dosimetry data 
was obtained from Monte Carlo simulation using the MCNP6 
code. Monte Carlo input files were prepared automatically 
from the parsing of information in the dicom RT data using a 
custom software tool (BrachyGuide). Personalized and TG-43 
based dose distributions were compared in the 3D anatomical 
space of each patient using isodose distributions, % dose 
difference maps, Dose Volume Histograms and relevant 
indices of clinical interest. The statistical and clinical 
significance of differences between personalized and TG-43 
based dosimetry in Co-60 HDR brachytherapy was examined, 
and evaluated relative to corresponding results for Ir-192. 
 
Results: Results indicated that the effect of tissue 
heterogeneities and patient specific scatter conditions is less 
for Co-60 than for Ir-192 HDR treatments. In general, Co-60 
and Ir-192 sources of identical shape and construction have 
been found to deliver clinically comparable dose distributions 
despite definite differences in their physical characteristics. 
This is confirmed in terms of personalized dosimetry in this 
study. A lower dose to critical organs close to the target by 
Co-60 sources was observed along with a small increase in the 
overdose volume (V150 to V400). The choice of isotope was 
not found to have an impact on the prescribed dose. 
 
Conclusion: Co-60 may be used as an effective alternative to 
Ir-192 for HDR brachytherapy, producing similar plans of 
equivalent target coverage, but with a logistical benefit and 
without the need for an image based algorithm for 
personalized dosimetry.  
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Purpose or Objective: The dose delivered to the cervix 
HRCTV is often limited by OAR tolerances. A new applicator 
with shields in the anterior and posterior areas of the ovoids 
has been developed to try to reduce OAR doses. The current 
dose calculation formalism (TG43) calculates dose to water 
and does not take into account tissue heterogeneity. The 
Advanced Collapsed cone Engine (ACE) is the Elekta 
implementation of TG186; it models tissue heterogeneity and 
the effect of shielding. 
 
Material and Methods: Eleven patients were selected that 
had received CT/MR planned brachytherapy for cervical 
cancer using Elekta Fletcher tube and ovoids. The HRCTV and 
OARs had been outlined on the MR. For this study the 
applicator library was used to perform a best fit match of the 
shielded CT/MR Fletcher tube and ovoid model with the CT of 
the insertion. The shielded applicators have a slightly 
different geometry compared to the unshielded Fletcher 
applicators. The 25mm shielded ovoids were overlaid on 
35mm standard ovoids and 30mm shielded ovoids were 
overlaid on 40mm standard ovoids.  
The dwell positions, dwell weights and A points were 
maintained from the clinical plan. The plans were calculated 
